Clinical and Therapeutic Impact of Large Genomic Studies at Diagnosis in Pediatric Solid Cancers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

230 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-06-20

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pediatric solid tumors with an unfavorable prognosis remain a public health issue due to their morbidity and mortality and their rapidly evolving profile. They are defined by an expected overall survival of \< 30%. Progress has been made in genomic medicine with existing recommendations for the adult population, with the objective of personalized medicine. Recommendations for the pediatric population are still under consideration

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Analyse of Tumour and Constitutional DNA for the Study of the Determinism in Child Neoplasia

NCT04471961

Pediatric Tumor Familial Cancer Solid Tumor, Childhood +1 more

ACTIVE_NOT_RECRUITING NA

Pilot Study of the Effect of Trastuzumab and GM-CSF on Children with Recurrent Ependymoma

NCT02774421

Posterior Fossa Ependymoma (PFEPN)

ACTIVE_NOT_RECRUITING PHASE1

Genomic Analysis of Pediatric Bone Tumors

NCT01047878

Bone Cancer

COMPLETED

Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors

NCT01962103

Neuroblastoma Rhabdomyosarcoma Ewing's Sarcoma +20 more

COMPLETED PHASE1/PHASE2

Gene Testing to Help in the Diagnosis and Treatment of Childhood Brain Tumors

NCT00003096

Brain Tumors Central Nervous System Tumors

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pediatric Solid Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients of pediatric age up to 22 years included at the time of molecular analysis
* Histological carcinological diagnosis performed at HUS
* Carcinological follow-up performed at HUS
* Patients with a solid tumor of unfavorable prognosis, refractory or in relapse
* Molecular analysis performed on tumor or blood samples
* Adult patients who do not object to the re-use of their personal data for medical research purposes
* Minor patients and their parents who do not object to the re-use of their personal data for scientific research purposes.

Criteria for non-inclusion

* Molecular biology results not usable due to poor sample quality or insufficient genetic material
* Patients who have expressed their opposition to participate in the study
* Parental authority holders who have expressed their opposition to participate in the study

Minimum Eligible Age

1 Year

Maximum Eligible Age

22 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No